Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity

v3.22.2.2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Capital in Excess of Par
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   39,759,000    
Beginning balance at Dec. 31, 2020 $ 711,002 $ 398 $ 3,222,959 $ (2,512,355)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (80,407)     (80,407)
Restricted stock units (in shares)   13,000    
Restricted stock units 2,609   2,609  
Warrant exercises (in shares)   6,385,000    
Warrant exercises 134,818 $ 64 134,754  
Ending balance (in shares) at Mar. 31, 2021   46,157,000    
Ending balance at Mar. 31, 2021 768,022 $ 462 3,360,322 (2,592,762)
Beginning balance (in shares) at Dec. 31, 2020   39,759,000    
Beginning balance at Dec. 31, 2020 711,002 $ 398 3,222,959 (2,512,355)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) 79,800      
Ending balance (in shares) at Sep. 30, 2021   46,291,000    
Ending balance at Sep. 30, 2021 933,029 $ 463 3,365,121 (2,432,555)
Beginning balance (in shares) at Mar. 31, 2021   46,157,000    
Beginning balance at Mar. 31, 2021 768,022 $ 462 3,360,322 (2,592,762)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (11,695)     (11,695)
Restricted stock units (in shares)   132,000    
Restricted stock units 961 $ 1 960  
Ending balance (in shares) at Jun. 30, 2021   46,289,000    
Ending balance at Jun. 30, 2021 757,288 $ 463 3,361,282 (2,604,457)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) 171,902     171,902
Restricted stock units (in shares)   2,000    
Restricted stock units 3,839   3,839  
Ending balance (in shares) at Sep. 30, 2021   46,291,000    
Ending balance at Sep. 30, 2021 $ 933,029 $ 463 3,365,121 (2,432,555)
Beginning balance (in shares) at Dec. 31, 2021 61,370,684 61,371,000    
Beginning balance at Dec. 31, 2021 $ 1,865,768 $ 614 4,012,358 (2,147,204)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) 39,737     39,737
Restricted stock units (in shares)   6,000    
Restricted stock units 2,790   2,790  
Common stock issued for Primexx Acquisition (in shares)   117,000    
Common stock issued for Primexx Acquisition 6,295 $ 1 6,294  
Ending balance (in shares) at Mar. 31, 2022   61,494,000    
Ending balance at Mar. 31, 2022 $ 1,914,590 $ 615 4,021,442 (2,107,467)
Beginning balance (in shares) at Dec. 31, 2021 61,370,684 61,371,000    
Beginning balance at Dec. 31, 2021 $ 1,865,768 $ 614 4,012,358 (2,147,204)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) $ 937,349      
Ending balance (in shares) at Sep. 30, 2022 61,607,450 61,607,000    
Ending balance at Sep. 30, 2022 $ 2,809,002 $ 616 4,018,241 (1,209,855)
Beginning balance (in shares) at Mar. 31, 2022   61,494,000    
Beginning balance at Mar. 31, 2022 1,914,590 $ 615 4,021,442 (2,107,467)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) 348,009     348,009
Restricted stock units (in shares)   244,000    
Restricted stock units (1,899) $ 2 (1,901)  
Common stock issued for Primexx Acquisition (in shares)   (22,000)    
Common stock issued for Primexx Acquisition (1,363)   (1,363)  
Ending balance (in shares) at Jun. 30, 2022   61,716,000    
Ending balance at Jun. 30, 2022 2,259,337 $ 617 4,018,178 (1,759,458)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) 549,603     549,603
Restricted stock units (in shares)   1,000    
Restricted stock units 3,893   3,893  
Common stock issued for Primexx Acquisition (in shares)   (110,000)    
Common stock issued for Primexx Acquisition $ (3,831) $ (1) (3,830)  
Ending balance (in shares) at Sep. 30, 2022 61,607,450 61,607,000    
Ending balance at Sep. 30, 2022 $ 2,809,002 $ 616 $ 4,018,241 $ (1,209,855)